

J. Seeler's

June 6, 1978

Donald F. Klein, M.D.
New York State Psychiatric Institute
722 West 168 Street N
New York City

Dear Don,

Thank you for the corrections of the Hillside data. At this juncture, I cannot recall for sure what the question was to which the answer was incorrect, but I do recall the data, more or less, as you note in your letter. Whatever the effects were, and we were impressed with the antidepressant activity of chlorpromazine plus procyclidine, the marketplace, and our own activities since, indicate that we were not that impressed with the effects. I think what I tried to say was that if antipsychotic drugs are active as antidepressants they must do so on some subset of patients, if at all.

As you note, our failure to find a difference between imipramine and CPZ was interpreted as an antidepressant action for CPZ. I guess we would be more cautious about that interpretation now.

In any case, I thank you. I do believe that on toxicity alone, mianserin deserves a rapid and determined appraisal in this country. If it is true that it is antidepressant and if its cardiac and anticholinergic effects are indeed lower, we should use it in preference to the present TCAD. Good luck in your study.

I am committed to writing a summary for Psychopharm. Bulletin before June 30; so will send you a copy as soon as it done.

Take good care of Greg Asnis. He may be a scientist yet, especially if you nurture him.

Sincerely yours,

Max Fink, M.D.